Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists

Abstract

Medulloblastoma (MB) comprises four distinct molecular subgroups, and survival remains particularly poor in patients with Group 3 tumors. Mutations and copy number variations result in altered epigenetic regulation of gene expression in Group 3 MB. Histone deacetylase inhibitors (HDACi) reduce proliferation, promote cell death and neuronal differentiation… (More)
DOI: 10.1007/s00381-015-2963-4

Topics

2 Figures and Tables

Cite this paper

@article{Jaeger2015ViabilityOD, title={Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists}, author={Mariane da Cunha Jaeger and Eduarda C. Ghisleni and L{\'i}via Fratini and Algemir Lunardi Brunetto and Lauro Jos{\'e} Gregianin and Andr{\'e} Tesainer Brunetto and Gilberto Schwartsmann and Caroline Brunetto de Farias and Rafael Roesler}, journal={Child's Nervous System}, year={2015}, volume={32}, pages={61-64} }